ArticleNature communications2026
Soluble uric acid suppresses neutrophil-mediated host defense in sepsis.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neutrophils in Kidney Disease: Linking Neutrophil Function and Microenvironment to Therapeutic Targets.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Neutrophils are essential for host defense and inflammation, yet their dysfunction is a hallmark of acquired immunodeficiency in kidney disease, contributing to increased susceptibility to infections such as peritonitis, sepsis, and pneumonia. We speculated that impaired renal clearance of the metabolite soluble uric acid (sUA) accounts for neutrophil dysfunction. Indeed, hyperuricemia (HU, serum UA of 9-14 mg/dL) related or unrelated to kidney disease significantly exacerbates the inflammatory immune response in mice with endotoxemia and bacterial sepsis. Despite promoting hyperinflammation, HU simultaneously impairs host defense, an effect that is partially reversible by lowering UA levels with febuxostat. We validated these findings in vitro using neutrophils or serum from healthy individuals or hyperuricemic patients with chronic kidney disease. Depleting UA partially restores neutrophil function. Mechanistically, sUA promotes neutrophil activation and degranulation but impairs phagocytosis, leading to reduced NOX2 expression independent of intracellular MPO levels. This results in diminished ROS production and defective bacterial clearance in human neutrophils. In contrast, sUA has no impact on neutrophil extracellular trap formation following exposure to LPS or E.coli. Together, our findings identify HU as an immunometabolic regulator that amplifies hyperinflammation, while simultaneously impairing effective host defense, suggesting that targeting UA may help to overcome acquired immunodeficiency in kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.